Team Members

Principal Investigator

Dr. Greg Thurber

gthurber AT
Associate Professor of Chemical Engineering
Associate Professor of Biomedical Engineering
Harvard Medical School, Massachusetts General Hospital: T32 Traineeship in Molecular Imaging
Ph.D, Massachusetts Institute of Technology
BS, Pennsylvania State University

Graduate Students

Reginald Evans

An ideal diagnostic imaging technique would be safe, inexpensive, and provide both molecular and spatial information to the physician. Current diagnostic imaging technologies are expensive, time consuming and/or lack molecular information to aid in the diagnosis. My research focuses on developing novel, inexpensive, and convenient (for improved compliance) optical diagnostic agents to detect inflammatory diseases such as rheumatoid arthritis and monitor treatment response.

Ian Nessler

The tumor microenvironment is abnormal and complex. Unorganized and hyperpermeable tumor vasculature leads to uneven drug distribution and less effective treatment. I am investigating the use of combination therapies to modulate the tumor vasculature to increase efficacy. Understanding the temporal dependence of combination therapy can elucidate optimal windows of delivery to improve current and future cancer therapies.

Marshall Case

I am working on molecular engineering of peptide and protein therapeutics.

Anna Kopp

I am working on antibody drug conjugates and immunotherapy agents

Celia Shujun Dong

Antibody-drug conjugates can stimulate immune system via interaction between FcRs and Fcs. Previous research has proved that the payloads (drug) also have the potential to encourage immune response. I'm making a head to head comparison of different payloads on their abilities to stimulate dendritic cells which, due to their antigen-presenting mechanism, are important in the entire process of immune response. I'm also using pharmacokinetic model and will be using a hybrid angent-based model to do some simulation.

Co-advised by Prof. Jennifer Linderman

Haolong Huang

I am working on peptide engineering.

Jane Kwon

Antibody-drug conjugates (ADC) have the advantage of targeting tumor cells and directly delivering payloads (drugs) into them. However, we often confront the challenges of the uneven distribution of ADC and less efficient penetration. Analyzing the transport properties of ADC as well as understanding its interaction with the immune system is significant for improving the drug efficacy. I am working on the characterization of antibody-drug conjugates for enhanced distribution in the cancer cells and immune responses.

Melissa Calopiz

Using agent-based modeling, I will be studying the relationship between antibody drug conjugates and immune cells for cancer therapies. This model will be able to predict the impact of ADC drug distribution in tumors and capture improved responses with increased tissue penetration.

Co-advised by Prof. Jennifer Linderman

Generic placeholder image

Baron Rubahamya

A number of antibody-drug conjugates (ADCs) have been approved by the FDA and more are in early clinical trials and preclinical development. An important aspect about ADCs is their ability to combine the potency of small molecules and the targeting of antibodies. I am studying the characteristics of ADCs and the factors within the tumor microenvironment that affect and influence their efficacy as anti-cancer agents.

Generic placeholder image

Tiexin Wang

I am working on protein engineering and antibody drug conjugates.

Co-advised by Prof. Peter Tessier

Generic placeholder image

Jiakun Guan

I am working on the protease-activated T-Cell Engager that cross-link tumor cells with T-Cells via a bispecific protein therapeutic. A working system pharmacology model will be developed to capture the systemic distribution of it and to validate uptake and distribution in a mouse xenograft model.

Current Undergraduates

Matt Ratanapanichkich
Matthew Proefke

Undergraduate Alumni

Sophie Gable, (2019-2020)
Hannah Levy, (2019-2020)
Rohan Perisetla, (2019)
Zhongyuan Zhang, (2016-2017)
Nadia Auchus, (2015-2016)
Hans Guo, (2015-2016)
Jianshan Liao, (2014-2016)
Dyanne Neoh, (2014-2015)
Matt Riley, (2013-2014)
Allison DuRoss, (2012-2014)
Darby McKernan, (2019-2020)
Rahul Gopinath, (2018-2020)
Neelay Patel, (2019)
Andrew Min, (2016-2018)
Daniel Tresnak, (2015-2017)
Nik Christodolu, (2015-2016)
Victoria Eniola, (2016)
Liz Goulston, (2015-2016)
Aaron Priluck, (2013-2015)
Rachel Blaisdell, (2014)

Graduate Alumni

Dr. Bruna Menezes/Scheuher, Ph.D 2020, now at Applied Biomath

Dr. Eshita Khera, Ph.D 2020, now at Novartis

Yinuo Chen, Masters 2020

Dr. Lydia Atangcho, Ph.D 2020, now at BCG

Dr. Tejas Navaratna, Ph.D 2020, now a post-doc at UCSB

Dr. Mukesh Mahajan, Postdoctoral researcher (2019)

Dr. Cornelius Cilliers, Ph.D 2018, now at Mirati Therapeutics

Dr. Sumit Bhatnagar, Ph.D 2018, now at AbbVie

Dr. Liang Zhang, Ph.D 2017, now at AbbVie

Emily Deschenes, Masters 2016

Dr. Kirti Dhingra, Postdoctoral Fellow (2013-2014)